No headlines found.
Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024
ACCESSWIRE (Wed, 15-May 6:20 AM ET)
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
Globe Newswire (Tue, 14-May 8:30 AM ET)
Bayer and Evotec Collaborate to Advance Precision Cardiology
ACCESSWIRE (Tue, 30-Apr 2:50 AM ET)
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
ACCESSWIRE (Wed, 24-Apr 1:40 AM ET)
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
ACCESSWIRE (Tue, 23-Apr 3:01 PM ET)
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments
ACCESSWIRE (Thu, 18-Apr 7:47 AM ET)
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
PRNewswire (Thu, 18-Apr 7:27 AM ET)
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
ACCESSWIRE (Wed, 17-Apr 9:19 AM ET)
Evotec welcomes Aurlie Dalbiez as Chief People Officer
ACCESSWIRE (Wed, 17-Apr 1:50 AM ET)
ACCESSWIRE (Wed, 6-Mar 1:51 AM ET)
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 65% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 35% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Evotec Se - American Depositary Shares Each Representing 1/2 Of One Ordinary Share trades on the NASDAQ stock market under the symbol EVO.
As of May 14, 2024, EVO stock price climbed to $5.55 with 163,358 million shares trading.
EVO has a beta of 1.51, meaning it tends to be more sensitive to market movements. EVO has a correlation of 0.10 to the broad based SPY ETF.
EVO has a market cap of $1.96 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that EVO belongs to (by Net Assets): APIE.
EVO has underperformed the market in the last year with a return of -45.5%, while the SPY ETF gained +28.8%. In the last 3 month period, EVO fell short of the market, returning -23.6%, while SPY returned +5.3%. However, in the most recent 2 weeks EVO has outperformed the stock market by returning +6.9%, while SPY returned +4.2%.
EVO support price is $5.21 and resistance is $5.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVO stock will trade within this expected range on the day.